Novelos Therapeutics, Inc. (OTC BB: NVLT)

Novelos Therapeutics, Inc. (OTC BB: NVLT), a biopharmaceutical company, has its focus on commercializing oxidized glutathione-based compounds for the treatment of Cancer and Hepatitis. The company’s lead compound in Phase 3 development for lung cancer under a Special Protocol Assessment (SPA) and Fast Track, NOV-002, acts together with chemotherapy as a chemoprotectant and chemopotentiator by regulating redox-sensitive cell signaling pathways. For further information, visit the Company’s web site at www.novelos.com.